Koninklijke Philips
PHG · NYSEX-Ray Apparatus & Tubes & Related Irradiation Apparatus · Fiscal year ends Dec 31 · Reports in EUR
Koninklijke Philips reported revenue of EUR 17.8B in the fiscal year ended Dec 2025, down 1.0% from the year before. Operating income was EUR 1.4B, an operating margin of 8.0%, and net income was EUR 897M.
Last 5 fiscal years
Revenue and net income
Income statement
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | EUR 17.2B | EUR 17.8B | EUR 18.2B | EUR 18B | EUR 17.8B |
| Cost of revenue | EUR 10B | EUR 10.6B | EUR 10.7B | EUR 10.2B | EUR 9.8B |
| Gross profit | EUR 7.2B | EUR 7.2B | EUR 7.4B | EUR 7.8B | EUR 8.1B |
| Research & development | EUR 1.8B | EUR 2.1B | EUR 1.9B | EUR 1.7B | EUR 1.7B |
| Operating income | EUR 553M | −EUR 1.5B | −EUR 115M | EUR 529M | EUR 1.4B |
| Interest expense | EUR 159M | EUR 235M | EUR 277M | EUR 288M | EUR 288M |
| Pre-tax income | EUR 509M | −EUR 1.7B | −EUR 526M | EUR 123M | EUR 1.2B |
| Income tax | −EUR 103M | −EUR 113M | −EUR 73M | EUR 963M | EUR 282M |
| Net income | EUR 3.3B | −EUR 1.6B | −EUR 463M | −EUR 698M | EUR 897M |
Balance sheet
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | EUR 2.3B | EUR 1.2B | EUR 1.9B | EUR 2.4B | EUR 2.8B |
| Receivables | EUR 3.8B | EUR 4.1B | EUR 3.7B | EUR 3.7B | EUR 3.5B |
| Inventory | EUR 3.5B | EUR 4B | EUR 3.5B | EUR 3.2B | EUR 2.9B |
| Current assets | EUR 10.3B | EUR 10.3B | EUR 9.9B | EUR 10B | EUR 9.9B |
| Net PP&E | EUR 2.7B | EUR 2.6B | EUR 2.5B | – | – |
| Goodwill | EUR 10.6B | EUR 10.2B | EUR 9.9B | EUR 10.4B | EUR 9.3B |
| Total assets | EUR 31B | EUR 30.7B | EUR 29.4B | EUR 29B | EUR 26.9B |
| Payables | EUR 1.9B | EUR 2B | EUR 1.9B | EUR 1.8B | EUR 1.9B |
| Current liabilities | EUR 7.5B | EUR 7.9B | EUR 8.3B | EUR 8.1B | EUR 7.5B |
| Total liabilities | – | – | EUR 17.3B | EUR 16.9B | EUR 16B |
| Shareholders' equity | EUR 14.4B | EUR 13.2B | EUR 12B | EUR 12B | EUR 11B |
Cash flow
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Capital expenditure | EUR 397M | EUR 444M | EUR 345M | EUR 317M | EUR 269M |
Key ratios
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | 3.9% | 1.9% | −0.8% | −1.0% |
| Operating income growth (YoY) | – | −376.5% | – | – | 169.2% |
| Gross margin | 41.8% | 40.4% | 41.0% | 43.1% | 45.2% |
| Operating margin | 3.2% | −8.6% | −0.6% | 2.9% | 8.0% |
| Net margin | 19.4% | −9.0% | −2.5% | −3.9% | 5.0% |
| Return on equityBlank when equity is negative | 23.0% | −12.1% | −3.8% | −5.8% | 8.2% |
| ROCEEBIT ÷ (assets − current liabilities) | 2.4% | −6.7% | −0.5% | 2.5% | 7.3% |
| Receivable days | 81 | 84 | 75 | 74 | 72 |
| Inventory days | 126 | 139 | 119 | 114 | 107 |
| Payable days | 68 | 68 | 65 | 65 | 72 |
| Interest cover | 3.48x | −6.51x | −0.42x | 1.84x | 4.94x |
| Current ratio | 1.39x | 1.29x | 1.20x | 1.23x | 1.32x |
Recent filings
More in X-Ray Apparatus & Tubes & Related Irradiation Apparatus
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.